News & Insights

Daryl-Ashlee's reflections on her placement as part of her NHS Graduate Management Trainee Scheme at DHT.health collaborating with those who have a rare and underserved disease.

DHT.health launch Evidence and Insights programmes, a multi-country initiative built to capture patient voice, lived experience and outcomes in rare and underserved diseases.

DHT.health recognised among Grant Thornton’s Top 100 “Ones to Watch” in the UK Pharma Services Sector

Inherited bleeding disorders (iBDs), such as haemophilia A and B, von Willebrand disease (VWD), and Glanzmann thrombasthenia, present unique challenges for health technology assessment (HTA). Treatments are often lifelong, costly, and evolving rapidly, especially with the advent of gene therapies and non-factor replacement options like emicizumab. Economic evaluations (EEs) are essential to guide reimbursement and policy decisions, and modelling plays a central role in these

Patient Reported Outcomes in understanding lived experiences of individuals with a health condition.

Patient-Generated Data and Preferences in Europe's evolving HTA landscape.

In the rapidly evolving landscape of healthcare, patient-centricity is more than just a buzzword—it's becoming the cornerstone of...

The U.S. Food and Drug Administration (FDA) is setting a new standard for patient-centred care with its recently updated draft guidance...

Sickle cell disease (SCD) is a devasting genetic disorder. This article looks at the economic impact of SCD in Sub-Saharan Africa.